Shape the future of respiratory health. After a successful European Pulmonary Fibrosis Federation Congress in April in Belgium, we are excited to announce our participation in the next American Thoracic Society Congress 2026 in Orlando, Florida from May 15-20, 2026! 🌟 Our Head International Commercial Operations Emmanuel BAERT will be there. Happy to meet with you and explore how we can improve the life of patients living with respiratory diseases! Please contact Emmanuel to organize a meeting at emmanuel.baert@hacpharma.com. Follow us to see where this journey takes us! #ATS2026 #AmericanThoracicSociety #RareDiseases #PharmaNetworking #earlyaccess #marketaccess #registration #distribution #inlicensing #acquisition #pharma #europe #exploitant #innovation #biotechs #businessdevelopment
HAC Pharma
Fabrication de produits pharmaceutiques
Caen, Normandy 1 783 abonnés
Notre mission : le maintien et/ou la mise à disposition de médicaments à valeur ajoutée thérapeutique importante
À propos
H.A.C. Pharma est un laboratoire pharmaceutique Français indépendant ayant les statuts d’exploitant, d’importateur et de fabricant. Depuis sa création en 2007, H.A.C. Pharma met sur le marché des médicaments à forte valeur ajoutée, matures et/ou innovants, issus d’accords de distribution, de licence ou d’acquisition. H.A.C. Pharma a un positionnement unique, couvrant l’ensemble de la chaine de valeur de la commercialisation de médicaments sur le marché français : de la stratégie d’enregistrement et d’accès au marché, en passant par l’importation et la distribution, et incluant au besoin le marketing et la promotion. Nous mettons sur le marché des médicaments de spécialité, promus auprès de spécialistes à l’hôpital ou en ville, principalement en endocrinologie, neuropsychiatrie, gynécologie, onco-hématologie et gastroentérologie. Nous travaillons aussi avec un réseau de distributeurs partenaires dans 6 pays Européen (Espagne, Italie, Belgique, Autriche, Suisse et Portugal).
- Site web
-
https://www.hacpharma.com
Lien externe pour HAC Pharma
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Caen, Normandy
- Type
- Société indépendante
- Fondée en
- 2007
- Domaines
- Specialty pharmaceuticals, Early access, Orphan drugs status, Compassionate use, Medical evaluation, Market access, Pricing and reimbursement, In-licensing, Distribution, Acquisitions, M&A, Supply chain, Tech transfer, CMO management, Medical promotion, Guidelines, Product development, Established brands et Innovative therapeutics
Lieux
-
Principal
Obtenir l’itinéraire
14000 Caen, Normandy, FR
Employés chez HAC Pharma
Nouvelles
-
Thank you Business France North America for your support!
[#BIO2026] 💊 Biotechs: Part 3! Meet 10 innovative biotech companies joining the French Pavilion at BIO 2026! Dolinnov aims to develop an innovative therapeutic approach based on antisense technology to treat chronic pain, particularly neuropathic and inflammatory pain. Grégoire Serra ENEMSA PHARMA is a pharmaceutical company (formerly known as New Inflectis) dedicated to the discovery and development of innovative therapeutics for the treatment of severe protein misfolding diseases and neurological disorders. Pierre Miniou Exeliom Biosciences is a clinical-stage immunotherapy company developing EXL01, a NOD2-targeting, single-strain live biotherapeutic designed to enhance the efficacy of checkpoint inhibitors by reprogramming macrophages. Benjamin Hadida HAC Pharma is a European independent pharmaceutical company with a successful track record in launching and marketing drugs in Europe, following an approach structured around healthcare professionals, medical societies, and authorities, to ensure optimal access to treatment for patients. François HUGUET Hemerion Therapeutics is a clinical-stage company developing an innovative photodynamic therapy that combines a proprietary photosensitizer drug and a specific laser system to treat glioblastoma and other solid tumors. Maximilien Vermandel HEPHAISTOS-Pharma is a biotech company developing 3rd generation innate immune boosters designed to convert myeloid-rich tumors into immunotherapy responsive tumors. Simon Pico Igyxos is a biotechnology company dedicated to developing first-in-class, innovative treatments for female and male infertility. Their unique technology utilizes monoclonal antibodies to significantly potentiate the bioactivity of endogenous and exogenous gonadotropins. Florent Ferré Kahimmune Therapeutics is an immuno-oncology company developing next-generation shared mRNA cancer vaccines. They identify exclusive new tumor antigens from the non-coding "dark" genome to design companion therapies for solid tumors. Philippe Villain-Guillot Lys Therapeutics develops first-in-class therapies for neurodegenerative and neurovascular diseases by restoring blood-brain barrier integrity and counteracting neuroinflammation. Manuel Blanc Mabqi focuses on the discovery and development of fully human antibodies. Its AI-powered platform enables the tackling of complex targets, the exploration of next-generation antibody formats, and the generation of highly developable drug candidates. Sylvain Yon Eurobiomed - Atlanpole Biotherapies - France Biotech - Lyonbiopôle Auvergne-Rhône-Alpes #FrenchHealthcare #Biotech #Healthcare
-
-
A defining moment for patients with pulmonary fibrosis. At HAC Pharma, we promote a “no patient left behind” approach to ensure access of treatments for patients with reduced or no alternatives. Pulmonary fibrosis is still an area of significant unmet need, but change is coming. We are excited to announce our participation in the European Pulmonary Fibrosis Federation (EU-PFF) Congress Europe 2026 in Brussels from April 24-26, 2026! 🌟 Our Head Strategy and BD François HUGUET was there. Happy to meet with you and discuss improving access to treatments for patients with pulmonary fibrosis. #EU-PFF #EuropeanPulmonaryFibrosisFederation #OrphanDrug #RareDiseases #PharmaNetworking #earlyaccess #marketaccess #registration #distribution #inlicensing #acquisition #pharma #europe #exploitant #innovation #biotechs #businessdevelopment
-
-
🎓 Fierté & Transmission chez HAC Pharma Nous avons eu le plaisir d’accompagner Sofiane Sana, ancien stagiaire puis alternant au sein d’HAC Pharma, dans une étape déterminante de son parcours : la soutenance de sa thèse de Docteur en Pharmacie. Notre CEO, Philippe BISSAY, a eu l’honneur de siéger au jury aux côtés de deux professeurs éminents de la Faculté de Pharmacie de Caen. Un moment fort, autour d’un sujet qui nous tient particulièrement à cœur et reflète l’engagement d'HAC Pharma pour l’innovation, la qualité et la formation des futurs professionnels de santé. 🙌 Un immense bravo à Sofiane pour ce travail remarquable et pour son parcours au sein de nos équipes. 📚 Chez HAC Pharma, nous sommes fiers de soutenir la Faculté de Pharmacie de Caen et de contribuer, à notre échelle, à la formation des talents de demain. Université de Caen Normandie
-
-
“CAR T-cells neurological symptoms: opportunity or threat?” What an incredible week in San Francisco from January 12–14, 2026! 🌉✨ HAC Pharma was proud to take part in the French Healthcare Days during J.P. Morgan Week 2026. We were impressed by the quality and diversity of the discussions, from the highly scientific exchanges at the Café des Sciences organized by the Consulate General of France in San Francisco, to the investor-focused conversations at the J.P. Morgan conference. A big thank you to everyone who met with us: innovators, partners, investors, and fellow healthcare leaders. Your insights and ambitions continue to drive our mission: accelerating market access in Europe for breakthrough healthcare solutions. Our CEO Philippe BISSAY and our Head of Strategy & Business Development François HUGUET had the pleasure of connecting with inspiring teams and exploring new collaborations that we look forward to developing in the coming months. 📩 If we didn’t get the chance to meet during the event, feel free to reach out to our BD team at bd@hacpharma.com. Follow us for updates on this exciting journey! Thank you Business France North America! #CaféDesSciences #earlyaccess #marketaccess #registration #distribution #inlicensing #acquisition #pharma #europe #exploitant #france #BusinessFranceNorthAmerica #FrenchHealthcare #innovation #biotechs #businessdevelopment
-
-
First office in a European capital city! 📍 New address: 69 boulevard Haussmann, Paris, France HAC Pharma continues its strong growth trajectory, and we are proud to announce the opening of our new office in Paris, France. This presence in a major European capital city marks an important milestone for our company: it will allow us to be even closer to our partners, increase our responsiveness, and strengthen our day‑to‑day collaboration. A big thank you to all the teams who made this opening possible, in particular Officehunter, Clara Marchand and Constance Vantorre. 🙌 We look forward to welcoming you there soon! #earlyaccess #marketaccess #registration #distribution #inlicensing #acquisition #pharma #europe #exploitant #innovation #biotechs #businessdevelopment
-
-
HAC Pharma is excited to announce our participation in WHX Dubai 2026, taking place from February 9–12, 2026! 🌍✨ Our CEO Philippe BISSAY and our Head of Marketing & International Business Emmanuel BAERT will be on the ground and eager to meet partners and industry leaders. Join us to discuss strategies to boost your market access in Europe and learn more about HAC Pharma’s expansion in the Middle East. 📩 To schedule a meeting, reach out to our BD team at bd@hacpharma.com. Follow us for updates on this exciting journey! #earlyaccess #marketaccess #registration #distribution #inlicensing #acquisition #distributors
-
-
Happy New Year 2026! ✨ A New Year, A Renewed Commitment to Patients ✨ From the apothecary jars of yesterday to the advanced therapies of today, healthcare has always been about one thing: patients. As we enter this new year, let’s remember that innovation is not just about science, it’s about impact. Every breakthrough, every decision, every partnership must serve a single purpose: improving patients’ lives. ---------------------------------------------------------------------------------- Meilleurs vœux 2026 ! ✨ Une nouvelle année, un engagement renouvelé envers les patients ✨ Des pots d’apothicaires d’hier aux thérapies innovantes d’aujourd’hui, la santé a toujours reposé sur une seule priorité : les patients. Alors que nous entamons cette nouvelle année, rappelons-nous que l’innovation ne doit pas se limiter qu’à la science, elle doit viser l’impact. Chaque avancée, chaque décision, chaque partenariat doit servir un objectif unique : améliorer la vie des patients. #earlyaccess #marketaccess #registration #distribution #inlicensing #acquisition #pharma #europe #exploitant #innovation #biotechs #businessdevelopment
-
-
HAC Pharma a republié ceci
We’re thrilled to share that HAC Pharma will be participating in the French Healthcare Days during J.P. Morgan Week in San Francisco, January 12-14, 2026! 🌍✨ Our CEO Philippe BISSAY and our Head of Strategy & Business Development François HUGUET will be on-site and ready to connect! Let’s discuss how HAC Pharma can accelerate your market access in Europe! 📩 To schedule a meeting, reach out to our BD team at bd@hacpharma.com. Follow us for updates on this exciting journey! Business France North America #earlyaccess #marketaccess #registration #distribution #inlicensing #acquisition #pharma #europe #exploitant #france #BusinessFranceNorthAmerica #FrenchHealthcare #innovation #biotechs #businessdevelopment
-
-
We’re thrilled to share that HAC Pharma will be participating in the French Healthcare Days during J.P. Morgan Week in San Francisco, January 12-14, 2026! 🌍✨ Our CEO Philippe BISSAY and our Head of Strategy & Business Development François HUGUET will be on-site and ready to connect! Let’s discuss how HAC Pharma can accelerate your market access in Europe! 📩 To schedule a meeting, reach out to our BD team at bd@hacpharma.com. Follow us for updates on this exciting journey! Business France North America #earlyaccess #marketaccess #registration #distribution #inlicensing #acquisition #pharma #europe #exploitant #france #BusinessFranceNorthAmerica #FrenchHealthcare #innovation #biotechs #businessdevelopment
-